Oleg Zherebtsov, Founder and Chairman of the Board of Directors of Solopharm, took part in the panel discussion «Oncology 2030: How Russia Can Keep Pace in the Technological Race».
On October 5–6, 2026, the 3rd International BIOPROM Forum was held in Gelendzhik under the theme «Ecosystem for a High Quality of Life». The forum brought together representatives of government, business, and academia to advance technologies aimed at improving people's quality of life. Oleg Zherebtsov was among the speakers participating in the forum's business program.
During the panel discussion «Oncology 2030: How Russia Can Keep Pace in the Technological Race», participants explored the future of oncology and the role of advanced technologies in creating new opportunities for disease treatment.
Biotechnology is one of Solopharm's key strategic development areas. The company is building its own scientific and technological capabilities to develop complex pharmaceutical products, including monoclonal antibodies used in the treatment of cancer and autoimmune diseases.
Speaking at the forum, Oleg Zherebtsov also highlighted the scale of the Russian monoclonal antibody market, estimating its value at approximately RUB 300 billion. This segment remains a significant area of development in modern pharmaceuticals and offers substantial opportunities for Russian drug developers and manufacturers.
For Solopharm, advancing its biotechnology business is part of a long-term strategy focused on mastering complex technologies and expanding the capabilities of the Russian pharmaceutical industry. The company continues to invest in research, manufacturing infrastructure, and the expertise required to develop modern pharmaceutical products.
